Cytosorbents Corporation
CTSONASDAQHealthcare● Active
$0.41
$-0.04(-9.76%)
Market Cap$26009585
P/E Ratio—
52W High$1.39
52W Low$0.408
Cytosorbents Corporation (CTSO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTSO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.08
Est. -$0.06 · -33.3%
Revenue
$0.01B
Est. $0.01B · -5.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CTSO reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Nov 3, 2026 | -$0.03 | — | — | — | $0.01B | — |
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.05 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.06 | -$0.08 | -33.3% | $0.01B | $0.01B | -5.7% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -$0.05 | -$0.09 | -80.0% | $0.01B | $0.01B | -5.6% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.06 | -$0.04 | +33.3% | $0.01B | $0.01B | +2.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.07 | -$0.05 | +28.6% | $0.01B | $0.01B | +4.3% |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.08 | -$0.06 | +25.0% | $0.01B | $0.01B | -3.1% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.07 | -$0.03 | +57.1% | $0.01B | $0.01B | -35.3% |
Q4 FY2026
Nov 3, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
$0.01B
Q1 FY2026
Mar 25, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.05
EPS Surpr.
-80.0%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.06
EPS Surpr.
+33.3%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.07
EPS Surpr.
+28.6%
Revenue
$0.01B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
$0.01B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.07
EPS Surpr.
+57.1%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.03 | $0.03 | $0.03 | 1 |
| Q3 FY2028 | $0.03 | $0.03 | $0.03 | 1 |
| Q2 FY2028 | $0.03 | $0.03 | $0.03 | 1 |
| Q1 FY2028 | $0.03 | $0.03 | $0.03 | 1 |
| Q4 FY2027 | $-0.02 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $0.02 | $0.02 | $0.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -33.3% | $0.59 | $0.57 | -2.61% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -80.0% | $0.70 | $0.67 | -3.52% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +33.3% | $0.64 | $0.67 | +4.16% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +28.6% | $0.90 | $0.89 | -0.98% |
| ▲ Q2 FY2025 | May 14, 2025 | +25.0% | $0.87 | $0.81 | -7.11% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +57.1% | $1.00 | $1.00 | +0.00% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -14.3% | $0.92 | $0.90 | -1.76% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +11.1% | $0.89 | $0.90 | +0.43% |
Q2 FY2026-2.61%
Report Date
May 13, 2026
EPS Beat/Miss
-33.3%
Price Before
$0.59
Price After
$0.57
Q1 FY2026-3.52%
Report Date
Mar 25, 2026
EPS Beat/Miss
-80.0%
Price Before
$0.70
Price After
$0.67
Q4 FY2025+4.16%
Report Date
Nov 13, 2025
EPS Beat/Miss
+33.3%
Price Before
$0.64
Price After
$0.67
Q3 FY2025-0.98%
Report Date
Aug 7, 2025
EPS Beat/Miss
+28.6%
Price Before
$0.90
Price After
$0.89
Q2 FY2025-7.11%
Report Date
May 14, 2025
EPS Beat/Miss
+25.0%
Price Before
$0.87
Price After
$0.81
Q1 FY2025+0.00%
Report Date
Mar 31, 2025
EPS Beat/Miss
+57.1%
Price Before
$1.00
Price After
$1.00
Q4 FY2024-1.76%
Report Date
Nov 7, 2024
EPS Beat/Miss
-14.3%
Price Before
$0.92
Price After
$0.90
Q3 FY2024+0.43%
Report Date
Aug 13, 2024
EPS Beat/Miss
+11.1%
Price Before
$0.89
Price After
$0.90
Avg Beat Reaction-0.70%
Avg Miss Reaction-2.63%
Beat Rate5 / 8 quarters
Largest Move-7.11% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTSO ends December
Cytosorbents Corporation (CTSO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.08 — missing the analyst consensus of $-0.06 by -33.3%. The next CTSO earnings date is expected around September 1, 2026.
Each quarter, investors track CTSO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTSO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTSO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTSO earnings · 5 questionsCytosorbents Corporation's next earnings report is expected around September 1, 2026. CTSO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTSO historically reports after market close (AMC).
CTSO earnings datewhen is CTSO earningsCTSO next earnings datewhen does CTSO report earningsCTSO earnings calendar
▸ Source: FMP · Cytosorbents Corporation SEC filings · US GAAP · Cytosorbents Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026